Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Researchers identify gene behind childhood brain diseases
Discovery of the PLA2G6 gene, whose mutated forms trigger several genetic disorders categorized as neuroaxonal dystrophies, could also shed light on the nerve cell degeneration that leads to
Discovery of the PLA2G6 gene, whose mutated forms trigger several genetic disorders categorized as neuroaxonal dystrophies, could also shed light on the nerve cell degeneration that leads to
Data from the ongoing study indicate that the combination regimen, known as VELSAM, was well tolerated at doses studied to date and demonstrated anti-tumor activity, with 50% of
The researchers found that almost two-thirds of patients with REM sleep behavior disorder (RBD) develop degenerative brain diseases by approximately 11 years after diagnosis of RBD. “Hopefully, early
Vaccines based on this model might therefore be suitable for stockpiling for use during a pandemic until a new vaccine could be developed specifically against the variant causing
The drug has specifically been approved as a once-daily adjunct therapy for Parkinson’s disease patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response
Data presented by the company at the European Cystic Fibrosis Conference in Copenhagen, Denmark, highlight the significant anti-inflammatory activity discovered when each of the five candidate compounds is
Merck, which in March made its own bid for Schering, agreed to sell its recently increased stake in Schering for E89 per share. All Schering shareholders who had
Following a six-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using Hycamtin in combination with
DGAT-1 inhibitors modify lipid metabolism. The lead compound in the class, BAY 74-4113, is currently in phase I clinical development. Under the terms of the agreement, Bayer will
The Company currently is conducting clinical trials for this indication. Glycopyrrolate, an anticholinergic agent, also is approved as an adjunctive therapy in the treatment of peptic ulcers. The